Product Description: Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively[1][2][3].
Applications: Cancer-Kinase/protease
Formula: C28H36F2N8O3S
Citations: Biochem Biophys Rep. 27, September 2021, 101099/Biochem Biophys Res Commun. 2018 Sep 26;504(1):231-237. /Biochem Pharmacol. 2017 Jan 15;124:29-42./Biochim Biophys Acta. 2017 Nov 20;1865(2):354-363./bioRxiv. 2020 Jun./Cancer Res. 2016 Nov 15;76(22):6723-6734. /Cancer Res. 2023 Jun 29;CAN-23-0705./Cell Death Dis. 2019 Mar 20;10(4):271./Cell Rep. 2017 Oct 31;21(5):1386-1398./Cell Rep. 2022 Sep 13;40(11):111331./Cell. 2018 Nov 1;175(4):984-997.e24./Clin Cancer Res. 2024 May 8./EMBO J. 2022 Jan 5;e108946./Harvard Medical School LINCS LIBRARY/J Exp Clin Cancer Res. 2022 Apr 21;41(1):149./J Oncol. 2019 Jun 2;2019:5952836. /Mol Cell. 2017 Oct 19;68(2):336-349.e6./Mol Oncol. 2017 Aug;11(8):1035-1049./Nat Commun. 2017 Jun 27;8:15916./Nat Commun. 2019 Jun 28;10(1):2860./Nature. 2017 Aug 24;548(7668):471-475. /Nutrition. 2019 Apr;60:217-226. /Oncotarget. 2017 Jul 27;8(56):95116-95134. /Oncotarget. 2017 Jun 27;8(40):67422-67438. /Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./STAR Protocols. 2020 Jun 3;1(1):100024./ACS Appl Mater Interfaces. 2022 May 11;14(18):20628-20640./Adv Funct Mater. 2021 Apr 30./Adv Sci (Weinh). 2020 Aug 4;7(18):2000906./Adv Sci (Weinh). 2022 Aug 2;e2201834./Bioact Mater. 8 September 2021./Biochem Biophys Res Commun. 20 December 2021./Biomed Chromatogr. 2020 Jun;34(6):e4825./bioRxiv. 2023 Jan 25./bioRxiv. 2023 Jul 17./bioRxiv. 2023 Jul 19./bioRxiv. 2024 Dec 10:2024.12.09.627542./bioRxiv. 2024 Nov 15:2024.11.11.623139./Blood Cancer J. 2022 Jan 11;12(1):5./Br J Cancer. 2022 Jan 14./Breast Cancer Res. 2019 Dec 26;21(1):150./Cancer Cell. 2024 Aug 27:S1535-6108(24)00305-2./Cancer Discov. 2023 Dec 4./Cancer Res. 2017 May 1;77(9):2488-2499./Cancer Res. 2019 Oct 15;79(20):5245-5259./Cancer Res. 2022 May 16;82(10):1890-1908./Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. /Cell Death Dis. 2020 Oct 28;11(10):925./Cell Rep. 2022 Dec 20;41(12):111826./Cell Rep. 2024 Dec 30;44(1):115116./Cell. 2023 Jun 8;186(12):2628-2643.e21./Commun Biol. 2021 Mar 25;4(1):399./Department of Biochemistry. 2020 Oct./EMBO J. 2024 Aug 19./EMBO J. 2024 Oct 24./Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11./Front Oncol. 2021 Jul 13;11:704042./Fundam Clin Pharmacol. 2021 Feb 1./Heliyon. 2023 Sep 13./Int J Biol Sci. 2019 Jan 1;15(3):522-532. /Int J Mol Sci. 2021 Jan 8;22(2):E575./Int J Mol Sci. 2022 Feb 24;23(5):2493./J Cell Biochem. 2023 Aug 11./J Med Chem. 2023 Mar 6./J Nanobiotechnology. 2025 Jan 3;23(1):3./J Oncol. 2022 Jun 23;2022:8724933./J Pharm Anal. 2024 Aug 22./JCI Insight. 2021 Dec 21;e154402./Leuk Res. September 2022, 106920./Mol Cancer Ther. 2024 Jun 19./Nat Commun. 2021 Aug 25;12(1):5112./Nat Commun. 2021 Nov 16;12(1):6607./Nat Commun. 2022 Aug 10;13(1):4689./Nat Commun. 2025 Jan 9;16(1):541./Nat Metab. 2020 Jan;2(1):41-49./Nature Cancer. 2021 Apr;2(4):429-443./Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4./NPJ Precis Oncol. 2021 Mar 19;5(1):20./Patent. US20200108066A1/R Soc Open Sci. 2019 Jan 23;6(1):181714./Sci Data. 2024 Sep 19./Sci Rep. 2022 Jul 20;12(1):12420./Sci Rep. 2024 May 8;14(1):10582./Sci Rep. 2019 Oct 22;9(1):15099. /SSRN. 2022 Nov 21./SSRN. 2023 Sep 29./Texas Southern University. 2024 July 02./Transl Lung Cancer Res. 2024 May 31;13(5):1032-1046./University of Gothenburg. 2023 Jun 27.
References: [1]Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13./[2]Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63./[3]Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37./[4]Wu T, et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017 Jan 15;124:29-42.
CAS Number: 1231930-82-7
Molecular Weight: 602.70
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 10 mg/mL (ultrasonic;warming;heat to 80°C)/H2O : 125 mg/mL (ultrasonic)
Target: CDK
Deutsch
English
